
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is a biopharmaceutical company with a promising pipeline of next-generation programmed T-cell therapies that are tailored to address specific diseases and improve patient outcomes. The company's recent virtual investor event highlighted the strong clinical profile of their lead therapy, Aucatzyl, and the potential for market expansion into earlier lines of therapy in pediatric ALL. Intellectual property protection and financial concerns are important risks to consider, but impressive real-world data and the potential for frontline use are positive indicators for the company's future success.
Bears say
Autolus Therapeutics is a biopharmaceutical company that is developing promising next-generation programmed T-cell therapies for cancer treatment, but there are several underlying risks and uncertainties. These include potential data readouts that may not meet expectations, competitive pressures from other companies with similar technologies, and potential safety concerns and adverse events associated with CAR-T therapy administration. Additionally, while initial data for their lead candidate AUTO3 in pediatric B-ALL patients has shown positive results, there is no guarantee of long-term and sustained remissions. Due to these risks, the outlook on Autolus's stock is negative from a financial analyst's perspective.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares